Tevogen Bio Holdings Inc. Warrant - TVGNW STOCK NEWS

Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, is set to provide important updates by the end of this week. These updates include:

1. Timelines for the previously announced revenue forecast for Tevogen Oncology and Tevogen Specialty Care therapeutic areas.

2. Details on Tevogen AI, their proprietary artificial intelligence initiative aimed at reducing drug development costs, accelerating drug discovery, and delivering therapies to large patient populations.

3. Information on clinical and commercial manufacturing progress.

The company had previously forecasted approximately $1 billion in revenue for each therapeutic area in their respective launch years, with a 5-year combined estimate between $28 billion and $36 billion.

Tevogen Bio, a clinical-stage specialty immunotherapy biotech (Nasdaq: TVGN), has announced its top-line revenue forecast for its specialty care pipeline. The company projects nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate between $18 billion and $22 billion. This forecast is in addition to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five years.

The forecast reflects Tevogen's unique, faster, and cost-efficient drug development model, which could serve as a blueprint for sustainable medical innovation. The company's pipeline includes treatments for SARS-CoV-2 infections in various patient groups, Long COVID, cervical cancer prevention, EBV-associated lymphomas, mouth and throat cancer, and multiple sclerosis.

Tevogen Bio (Nasdaq: TVGN) has clarified that the recent sale of shares by Chief Scientific Officer Dr. Neal Flomenberg was solely to satisfy tax obligations related to vesting restricted stock units, not a discretionary decision. The company's CFO, Kirti Desai, emphasized that other officers holding over 75% of outstanding shares have already paid taxes on granted shares and have no further obligation for similar sales. None of the company's officers have reduced their holdings since inception.

Tevogen recently released top-line revenue projections for its oncology therapeutic area, forecasting $1 billion in revenue for the launch year of its lead product candidate, with a 5-year cumulative estimate between $10-14 billion. The company plans to release similar forecasts for non-oncology areas soon. CEO Dr. Ryan Saadi highlighted the leadership team's retention of 100% equity as a sign of confidence in the company's potential, noting the significant market activity with over half a billion shares traded last week.

Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, has gained significant public support for its business model focused on developing accessible T cell therapeutics. The company's CEO, Dr. Saadi, expressed gratitude for the unprecedented trading volume of over half a billion shares this week. Tevogen's proprietary ExacTcell™ technology aims to create accessible, disease-specific cellular immunotherapies.

Key highlights include:

• 3 U.S. patents granted, 9 pending (including 2 for AI), and 12 international applications filed
• Positive proof-of-concept clinical trial data for the first product of its proprietary technology
• Officers hold nearly 79% of outstanding shares as of June 30, 2024
• Oncology forecast of $1 billion in launch year

Dr. Saadi reaffirmed his commitment to sharing additional progress details in the coming days.

Tevogen Bio, a clinical-stage specialty immunotherapy biotech (Nasdaq: TVGN), has announced its top-line revenue forecast for its oncology pipeline. The company projects $1 billion in revenue for the launch year and a cumulative 5-year estimate between $10 billion and $14 billion. This forecast is based on Tevogen's unique, faster, and cost-efficient drug development model.

The company's first pivotal study with TVGN 489 is designed to help cancer patients undergoing immunosuppressive treatments and chemotherapy combat SARS-CoV-2 infection. Tevogen's pipeline includes treatments for various cancers, rheumatoid arthritis, psoriatic arthritis, Long COVID, and multiple sclerosis.

Tevogen's approach reflects its business philosophy of achieving commercial success through patient accessibility. The total eligible patient population in the US exceeds 2 million.

Tevogen Bio and its CEO, Dr. Ryan Saadi, have been honored with a prestigious proclamation by Warren Township, New Jersey, for their innovative business model addressing health inequality. The company, nominated for the 2023 Nobel Peace Prize, has been recognized for establishing a multi-billion-dollar cell therapy biotech in Warren, NJ. Investors HMP Partners and The Patel Family LLP congratulated Tevogen, estimating the current market value of its intellectual property and product portfolio to exceed $10 billion.

Tevogen, previously named the highest-valued biotech unicorn at $4.2 billion in 2022, has achieved key milestones including granted patents and a product pipeline in multiple therapeutic areas. The company is preparing to share a multi-billion-dollar projected top-line revenue forecast. Tevogen's focus is on genetically unmodified personalized CD8+ Cytotoxic T lymphocytes for therapeutic purposes.

Tevogen Bio (Nasdaq: TVGN) is developing TVGN 920, a T cell therapy aimed at treating HPV in women with precancerous cervical lesions. This innovative treatment utilizes Tevogen's proprietary ExacTcell™ technology, employing genetically unmodified, allogeneic cytotoxic CD8+ CTLs targeting the HPV genome. The therapy's dual objectives are to prevent recurrent lesions that could lead to cervical cancer and eradicate HPV infection to halt virus transmission.

Key points:

• Approximately 1 in 3 women remain HPV positive after cervical procedures for precancerous lesions
• HPV is the primary risk factor for high-grade cervical lesion recurrence
• Tevogen aims to address this significant public health concern
• Success could pave the way for treatments of other virus-associated cancers

Tevogen Bio (Nasdaq: TVGN) highlights the publication of its phase I clinical trial data for TVGN 489, an investigational allogeneic SARS-CoV-2 specific CTL immunotherapy, in the journal Blood Advances. Key observations from the trial include:

- Faster symptom improvement and resolution in the treatment group compared to standard care
- Well-tolerated at all four doses tested
- High viral elimination rates (88%+ by day +4, >99% by day +14)
- No disease progression or Long COVID development in the treatment group
- Persistence of donor-derived CTLs through the 6-month follow-up period

The CEO, Ryan Saadi, expressed optimism about the company's ExacTcell™ platform, stating it represents a significant breakthrough in mainstreaming cell therapy through off-the-shelf T cell therapies for various applications.

Tevogen Bio (Nasdaq: TVGN), a clinical-stage biotech developing off-the-shelf T cell therapeutics, plans to update shareholders on its multi-billion dollar asset valuation following a recent $1b+ revenue potential announcement. CEO Ryan Saadi emphasizes the company's commitment to transparency and shareholder interests.

Key achievements include:

• Founding in 2020 and launch of proprietary ExacTcell technology
• 3 U.S. patents granted by 2022, with 9 pending and 12 international applications
• $4.2 billion valuation as highest valued biotech unicorn of 2022
• Positive proof-of-concept clinical trial results for TVGN 489 in 2023
• Introduction of Tevogen.AI and joining Microsoft for Startups program
• Public debut on Nasdaq in February 2024
• Inclusion in Russell 3000® Index

The company's pipeline includes treatments for SARS-CoV-2 infections, various cancers, and multiple sclerosis.